## Supporting Information

## Mitochondria-targeted delivery of doxorubicin and evodiamine for treatment of metastatic breast cancer

Xiaoyan Tan,<sup>#\*</sup> Yanlin Zhou,<sup>#</sup> Li Shen, Han Jia, and Xiaorong Tan

## **Supplementary Figure Captions:**

Fig. S1. <sup>1</sup>H NMR spectrum of TPP-COOH in DMSO-d6.

*Fig. S2.* <sup>1</sup>H NMR spectrum of TPP-Dex in DMSO-d6.

Fig. S3. <sup>1</sup>H NMR spectrum of SPCL in DMSO-d6.

Fig. S4. <sup>1</sup>H NMR spectrum of TPP-Dex-ss-SPCL in DMSO-d6.

*Fig. S5.* Zata potential of the mitochondrial-targeted stimulus-responsive copolymers TPP-Dex-ss-SPCL.

*Fig. S6.* A) Change in size distribution of TPP-Dex-ss-SPCL micelles in the presence of 10  $\mu$ M GSH in ABS at pH 5.0; B) Changes in size distribution of TPP-Dex-ss-SPCL micelles triggered by 10 mM GSH at pH 7.4.

*Fig. S7*. The critical micelle concentration (CMC) of the TPP-Dex-ss-SPCL micelles at A) pH 7.5 or B) pH 5.0 condition derived from the plot of I339 /I333 ratio vs. copolymer concentration using pyrene as the probe.

*Fig. S8*. Size changes of micelles after incubation in PBS (pH 7.4) or in cell culture medium (containing 10 % FBS, v/v) at 37°C for 5 days.

*Fig. S9.* Cytotoxicity of 4T1 cells treated by free drugs and drugs-loaded micelles as a function of DOX concentration (n = 3).

Fig. S10. Wound-healing assays showing that EVO inhibit the migration of 4T1 cells.

Table-S1. Characterizations of all the micelles.



Fig. S1. <sup>1</sup>H NMR spectrum of TPP-COOH in DMSO-d6.



Fig. S2. <sup>1</sup>H NMR spectrum of TPP-Dex in DMSO-d6.



*Fig. S3.* <sup>1</sup>H NMR spectrum of SPCL in DMSO-d6.



Fig. S4. <sup>1</sup>H NMR spectrum of TPP-Dex-ss-SPCL in DMSO-d6.

## Zeta Potential Distribution



*Fig. S5*. Zata potential of the mitochondrial-targeted stimulus-responsive copolymers TPP-Dex-ss-SPCL.



*Fig. S6.* A) Change in size distribution of TPP-Dex-ss-SPCL micelles in the presence of 10  $\mu$ M GSH in ABS at pH 5.0; B) Changes in size distribution of TPP-Dex-ss-SPCL micelles triggered by 10 mM GSH at pH 7.4.



*Fig. S7*. The critical micelle concentration (CMC) of the TPP-Dex-ss-SPCL micelles at A) pH 7.5 or B) pH 5.0 condition derived from the plot of I339 /I333 ratio vs. copolymer concentration using pyrene as the probe.



*Fig. S8*. Size changes of micelles after incubation in PBS (pH 7.4) or in cell culture medium (containing 10 % FBS, v/v) at 37°C for 5 days.



Fig. S9. Cytotoxicity of 4T1 cells treated by free drugs and drugs-loaded micelles as a function of DOX concentration (n = 3).



Fig. S10. Wound-healing assays showing that EVO inhibit the migration of 4T1 cells.

_		<b>.</b> .
Т	able	-S1

Sample name	Micelles size (nm)	PDI	Zeta potential(m V)	LC%	EE%
TPP-Dex-ss-SPCL	$85.7 \pm 1.8$	0.176±0.015	$+22.7\pm0.4$	—	—
Dex-ss-SPCL	$96.5 \pm 3.6$	$0.143 \pm 0.022$	$-12.9 \pm 0.3$		
TPP-Dex-SPCL	$88.6 \pm 2.5$	$0.194 \pm 0.035$	$+23.4\pm0.7$		—
Dex-SPCL	$82.9 \pm 4.6$	$0.158 \pm 0.014$	$-8.8 \pm 0.4$	—	—
TPP-Dex-ss- SPCL@DOX/EVO	89.5±2.6	$0.213 \pm 0.022$	$+24.4\pm0.5$	6.81±0.25% <sup>a</sup> 5.64±0.16 % <sup>b</sup>	76.42±3.12% <sup>a</sup> 62.68±2.35% <sup>b</sup>
Dex-ss-SPCL@DOX/EVO	99.3±3.1	$0.251 \!\pm\! 0.017$	-9.6±0.6	7.26±0.37% <sup>a</sup> 6.63±0.15 % <sup>b</sup>	79.44±3.27% <sup>a</sup> 73.92±2.85% <sup>b</sup>
TPP-Dex-SPCL@DOX/EVO	91.2±4.5	$0.226 \pm 0.025$	$+25.5\pm0.3$	6.46±0.22% <sup>a</sup> 5.12±0.19% <sup>b</sup>	72.04±3.35% <sup>a</sup> 56 97±2.82% <sup>b</sup>
Dex-SPCL@DOX/EVO	86.9±3.7	$0.217 \pm 0.019$	$-6.4 \pm 0.8$	7.34±0.27% <sup>a</sup> 6.46±0.18 % <sup>b</sup>	81.22±3.13% a 71.08±2.84% b

Micelles size, PDI and Zeta potential were all determined by DLS. a stands for DOX, and b stands for EVO.